Vericel Corp. (VCEL)

[cushsix]

June 2, 2011 7:46 AM EDT

Needham & Company maintains a 'Buy' on Aastrom Biosciences (NASDAQ: ASTM), PT $6.

Needham analyst says, "Last night, Aastrom reported 12-month results from the RCT Phase 2b RESTORE-CLI trial, evaluating the safety and efficacy of its
expanded, bone marrow-derived cellular therapy, ixmyelocel-T, in patients with critical limb ischemia (CLI). The final analysis of 86 enrolled patients showed a statistically significant improvement in time to treatment failure, the primary endpoint for the trial, as well as a benign safety profile. The detailed data including amputation free survival (primary endpoint for the upcoming pivotal trial) will likely be presented at a 4Q11 medical meeting...We believe that a series of upcoming company events may serve to drive investor interest in regenerative medicine as a whole and ASTM stock in particular."